02 April 2008 - As of the 1st of June 2008, Owen Mumford will be discontinuing two variants from their range of lancets within the UK market: Unilet Superlite (23G) and Unilet GP (21G)... Owen Mumford's Press Release -
Blog Archive
-
▼
2008
(233)
-
▼
April
(49)
- Echo : Prelude SkinPrep System, the Next-Generatio...
- Rigel's R788 : Preclinical Activity in Type 1 Diab...
- Pelikan and Lilly : Diabetes Education Alliance
- Smiths Medical to Promote and Distribute Abbott’s ...
- Medtronic : FDA Clearance of New OneTouch Ultralin...
- Metabasis Therapeutics : Extension of Its Collabor...
- Hadasit : Successful Phase I Study Results of a Ne...
- Innocoll : Phase 2 Clinical Trial to Investigate C...
- Pacira Pharmaceuticals and Amylin Pharmaceuticals ...
- Tolerx : Advancing Novel Type 1 Diabetes Agent int...
- Biovitrum : unique neuropathic pain compound is ve...
- SciGen and Generex : Distribution Agreement for Or...
- MetaCure : NewYork-Presbyterian/Weill Cornell Is F...
- GlaxoSmithKline to acquire Sirtris Pharmaceuticals...
- Medicure : Presentation of Phase II Matched Result...
- Daiichi Sankyo : Welchol Added to the ACE/AACE "Ro...
- AtheroGenics : Encouraging Interim Results From Ph...
- Pacific Biometrics : Research Contracts as Part of...
- AGI Therapeutics : key findings of clinical PK stu...
- Living Cell Technologies : Proprietary Nanobiocaps...
- Karo Bio : Positive Results in First Clinical Stud...
- Elixir Pharmaceuticals : National Diabetes Advisor...
- BioChemics & Beth Israel Deaconess Medical Center ...
- DiaKine : Lisofylline Reduces Obesity-Related Infl...
- PerkinElmer : New Innovations to Strengthen Drug D...
- Exelgen : Two New Major Drug Discovery Collaborat...
- Entelos : U.S. Patent for its Diabetes Model
- Kamada : AAT proved efficient in treating Type-1 ...
- Home Test Kits from BioIQ Help Consumers Detect Di...
- DiaKine Therapeutics & Kinexum Metabolics : Combin...
- 12-Month Data from Endeavor IV Show Strong Clinica...
- ArthroCareSports Medicine : to Tackle Diabetic Fo...
- WellDoc Communications : Diabetes Management Progr...
- Elixir Pharmaceuticals : enrollment in its final p...
- Pfizer Statement on Exubera Labeling Update in the US
- Diabetech Launches GlucoMON-RT Real-Time Monitorin...
- Luminous Medical : Automated Blood Glucose Monitor...
- Alimera Sciences and pSivida : DSMB again support...
- Metabolex : Phase 1 clinical trial of MBX-2982, Po...
- Takeda : ACTOS® (pioglitazone HCl) Prevented Progr...
- Cardium and Tissue Repair Company's Excellarate : ...
- Smiths Medical MD : voluntary recall of specific s...
- Owen Mumford Ltd : to discontinue Unilet GP and U...
- CV Therapeutics : New Data Shows Ranexa Increases ...
- Senesco : Preclinical Pancreatic Islet Data to be ...
- Aegera : Phase 1 Clinical Trial of AEG33773 - a Sm...
- Oculus Innovative Sciences : Chinese SFDA Regulato...
- BioMimetic Therapeutics Addresses FDA Communicatio...
- Novo Nordisk : FDA Approves NovoLog for Use in In...
-
▼
April
(49)
Friday, April 4, 2008
Owen Mumford Ltd : to discontinue Unilet GP and Unilet Superlite in UK market
02 April 2008 - As of the 1st of June 2008, Owen Mumford will be discontinuing two variants from their range of lancets within the UK market: Unilet Superlite (23G) and Unilet GP (21G)... Owen Mumford's Press Release -
Libellés :
Blood Glucose Monitoring,
Owen Mumford
